A traditional Chinese medicine compound and pharmaceutical preparation for treating chronic nephritis and nephrotic syndrome.
By vinegar treatment of the Chinese medicine compound composition green alum, alum, Glauber's salt and Baicao Cream, it was prepared into water pills or capsule dosage forms, which solved the shortcomings of the treatment of chronic nephritis and nephrotic syndrome in the prior art, significantly reduced blood CRE, blood BUN and Renal IgA deposition provides a safe and efficient treatment plan.
Patent Information
- Application Number
- CN202410456329.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-16
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-04-16
AI Technical Summary
The prior art lacks effective drugs for the treatment of chronic nephritis and nephrotic syndrome, which leads to gradual deterioration of renal function and is difficult to prevent and treat, and the existing treatment methods are complex and costly.
Provide a Chinese medicine compound prescription, consisting of green alum, alum, Glauber's salt, and Baicao Cream in a specific proportion, and is processed by vinegar to reduce side effects and enhance the efficacy. It is used to treat chronic nephritis and nephrotic syndrome, and is prepared into water pills, capsules or tablets. isoform.
It significantly reduces the deposition of blood CRE, blood BUN and kidney IgA, improves clinical symptoms, and provides a new drug choice for the prevention and treatment of chronic nephritis and nephrotic syndrome, with significant efficacy and good safety.
Smart Images

Figure CN118319961B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and more specifically, relates to a Chinese medicine compound and a pharmaceutical preparation for treating chronic nephritis and nephrotic syndrome. Background Art
[0002] Chronic nephritis, also known as chronic glomerulonephritis, can be manifested as basic clinical manifestations such as proteinuria, hematuria, and edema. Nephrotic syndrome (NS) is a clinical syndrome composed of glomerular diseases with various causes and pathological changes, generally manifested as massive proteinuria, severe edema, hyperlipidemia, and hypoproteinemia. Chronic kidney disease has become a public health problem that seriously endangers people's health. As the disease of chronic kidney disease prolongs, the lesions progress slowly, which can lead to varying degrees of renal function impairment, causing renal dysfunction, and eventually develop into chronic renal failure, which is difficult to recover and generally ends in nephrotoxicity. Patients with end-stage renal failure require long-term dialysis treatment or even kidney transplantation (kidney replacement); kidney transplantation is the best way to treat kidney failure, but kidney replacement is a complex project, and the success rate, kidney source, and cost are all big problems.
[0003] At present, there is no special treatment for chronic nephritis and nephrotic syndrome. The existing treatment mainly gives corresponding treatment according to its pathological type, inhibits immune-mediated inflammation, inhibits cell proliferation, and reduces renal sclerosis, with the main purpose of preventing or delaying the progressive deterioration of renal function, improving or alleviating clinical symptoms, and preventing and treating complications.
[0004] Therefore, the development of drugs that can effectively prevent and treat chronic nephritis and nephrotic syndrome is of great significance for patients with chronic kidney disease. Summary of the invention
[0005] The first object of the present invention is to provide a Chinese medicinal compound for treating chronic nephritis and nephrotic syndrome.
[0006] The second object of the present invention is to provide a medicine for treating chronic nephritis and nephrotic syndrome.
[0007] The above-mentioned purpose of the present invention is achieved through the following technical solutions:
[0008] The invention provides a traditional Chinese medicine compound, which is composed of green vitriol, alum, sodium sulfate and herb frost in the mass ratio of (97-104): (47-52): (23-27): (1-2).
[0009] Therapeutic drug research is usually conducted in animal models. Lipopolysaccharide (LPS), carbon tetrachloride (CCl 4 ) and bovine serum albumin (BSA) have been shown to be useful in establishing chronic nephritis models and nephrotic syndrome models.4 ) and bovine serum albumin (BSA) were used to induce a rat model to explore the effect of the Chinese herbal compound of the present invention on chronic nephritis and nephrotic syndrome.
[0010] In addition, through clinical observation of treatment of patients with chronic nephritis and nephrotic syndrome, the compound of the present invention can significantly improve indicators such as blood CRE, blood BUN, hematuria and urine protein, and improve clinical symptoms.
[0011] The results of the study showed that the above Chinese medicine compound had an effect on lipopolysaccharide (LPS), carbon tetrachloride (CCl 4 ) and bovine serum albumin (BSA)-induced chronic nephritis model rats have obvious preventive and therapeutic effects, mainly manifested in significantly reducing blood CRE, blood BUN and renal IgA deposition; in addition, it also has a good therapeutic effect on clinical chronic nephritis and nephrotic syndrome patients, and can significantly improve blood CRE, blood BUN, hematuria and urine protein and other indicators, and improve clinical symptoms. It can be seen that the Chinese medicine compound can be used for the treatment of chronic nephritis, especially IgA chronic nephritis, and nephrotic syndrome.
[0012] In this Chinese medicine compound, green vitriol is sour, astringent and cool in nature, can dry out dampness and resolve phlegm, eliminate stagnation, replenish blood, stop bleeding and detoxify; alum is bitter, sour and cold in nature, can dry out dampness and resolve phlegm, stop bleeding and astringe; mirabilite is bitter, salty and wet in nature, can eliminate stagnation and edema; Baicao frost is pungent and warm, can stop bleeding and eliminate stagnation. The combination of the four medicines has played a significant role in treating chronic nephritis.
[0013] Therefore, the use of the Chinese medicine compound in the preparation of a drug for treating chronic nephritis, in the preparation of a drug for treating IgA chronic nephritis, or in the preparation of a drug for reducing renal IgA deposition, in the preparation of a drug for treating kidney disease caused by renal IgA deposition, and in the preparation of a drug for treating nephrotic syndrome should all be within the scope of protection of the present invention.
[0014] Preferably, the Chinese medicine compound is composed of green vitriol, alum, sodium sulfate and herb frost in a mass ratio of (100-102):(48-50):(25-26):(1-2).
[0015] More preferably, the Chinese medicine compound of the present invention is also processed with vinegar, and the effect and purpose of the vinegar processing are: reducing side effects, enhancing therapeutic effects, and guiding meridians. The specific method of the vinegar processing is as follows:
[0016] (1) Mix green vitriol, alum and sodium sulfate, grind them into powder, mix them evenly with white vinegar, and the mass ratio of powder to white vinegar is (8-12):1;
[0017] (2) Then place it outdoors for 2-3 months without rain;
[0018] (3) After drying to a moisture content of less than 8%, add Baicao Frost and grind into powder.
[0019] In addition, based on this, the present invention also provides a pharmaceutical preparation for treating chronic nephritis and nephrotic syndrome, that is, a pharmaceutical preparation containing the above-mentioned Chinese medicine compound.
[0020] Optionally, the pharmaceutical preparation may be in the form of a water pill, a capsule or a tablet.
[0021] When preparing the drug preparation, the Chinese medicine compound is firstly processed according to the vinegar-making method, and then made into a pharmaceutical dosage form.
[0022] More specifically, as one of the optional solutions, the present invention provides a water pill, which is prepared by grinding the above-mentioned Chinese medicine compound into powder and processing. The specific preparation method of the water pill is as follows:
[0023] (1) Mix green vitriol, alum and sodium sulfate in proportion, grind into powder, mix evenly with white vinegar, the mass ratio of powder to white vinegar is (8-12):1;
[0024] (2) Then place it outdoors for 2-3 months without rain. The purpose of placing it outdoors is to get sunlight and ventilation.
[0025] (3) After drying to a moisture content of less than 8%, add the compound proportion of Baicao Frost and grind into a uniform powder;
[0026] (4) Add 0.5-1 times of water to the drug powder obtained in step (3), stir evenly, make pills, and dry at 40° C.-50° C. to obtain water pills of the Chinese medicine compound.
[0027] In particular, step (2) can be carried out by airing the product in a production workshop simulating outdoor lighting and ventilation conditions for 2-3 months.
[0028] The present invention has the following beneficial effects:
[0029] The present invention provides a Chinese medicine compound, which has a relatively obvious preventive and therapeutic effect on chronic nephritis, nephrotic syndrome and other kidney diseases, mainly manifested in significantly reducing blood CRE, blood BUN and kidney IgA deposition. The present invention provides a new drug selection for clinical chronic nephritis, nephrotic syndrome and other kidney disease prevention and treatment drugs.
[0030] Moreover, the Chinese medicine compound can be prepared into dosage forms such as water pills, capsules, and tablets. It has been verified through clinical treatment that it has significant efficacy, good safety, and very good application value and prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 . Blood biochemical test results (Mean±SD, n=8~10). Compared with the model group, ns: P>0.05, *: P<0.05, **: P<0.01, ***: P<0.001.
[0032] Figure 2 .Urine volume and urine biochemical test results (Mean±SD, n=8~10). Compared with the model group, ns:P>0.05, *:P<0.05, **:P<0.01, ***:P<0.001.
[0033] Figure 3 . Urine red blood cell count (Mean±SD, n=8~10). Compared with the model group, ns: P>0.05, *: P<0.05, ***: P<0.001.
[0034] Figure 4 . Representative images of renal tissue pathology HE staining (400×). A. Normal group, B. Model group, C. Low-dose Chinese medicine group, D. Medium-dose Chinese medicine group, E. High-dose Chinese medicine group, E prednisone acetate group.
[0035] Figure 5 . Renal histopathological scores (Mean±SD, n=8-10). Compared with the model group, ns: P>0.05, ***: P<0.001.
[0036] Figure 6 .Representative images of IgA immunofluorescence staining of renal tissue (400×). A. Normal group, B. Model group, C. Low-dose Chinese medicine group, D. Medium-dose Chinese medicine group, E. High-dose Chinese medicine group, F Prednisone acetate group. Green fluorescence is IgA-specific staining, and blue fluorescence is DAPI-stained nuclei.
[0037] Figure 7 . Mean fluorescence intensity of IgA in renal tissue (Mean±SD, n=8-10). Compared with the model group, ns: P>0.05, *: P<0.05, ***: P<0.001. DETAILED DESCRIPTION
[0038] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0039] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0040] Green vitriol, a traditional Chinese medicine, is a kind of ferrous sulfate (FeSO 4 ) ores or chemicals.
[0041] Alum, a traditional Chinese medicine name, potassium aluminum sulfate dodecahydrate.
[0042] Glauber's salt, a traditional Chinese medicine, is a crystal made by processing and refining the sulfate mineral Glauber's salt. It mainly contains hydrated sodium sulfate (Na 2 SO 4 10H 2 O).
[0043] Baicao Frost, a traditional Chinese medicine, also known as Fuqi Mo, is the black ash left after burning rice straw, wheat straw or weeds.
[0044] Example 1 Chinese medicine compound preparation
[0045] The Chinese herbal compound is composed of green alum, alum, sodium sulfate and herb frost in the ratio of 100:50:25:2 by mass.
[0046] A Chinese medicine compound preparation, specifically a water pill, is prepared as follows:
[0047] (1) Mix green vitriol, alum and sodium sulfate in appropriate proportions, grind into powder, mix evenly with white vinegar, and the mass ratio of powder to white vinegar is 10:1;
[0048] (2) Then place it outdoors for three months without rain. The purpose of placing it outdoors is to get some sun and ventilation (if it rains during this period, it needs to be brought indoors to avoid the rain);
[0049] (3) After drying to a moisture content of less than 8%, add the compound proportion of Baicao Frost and grind into a uniform powder;
[0050] (4) Add 1 times the amount of water to the drug powder obtained in step (3), stir evenly, make pills, and dry at 40° C. to obtain water-based pills of the Chinese medicine compound. The pill weight is 2 g.
[0051] Example 2 Chinese medicine compound preparation
[0052] The Chinese herbal compound is composed of green vitriol, alum, sodium sulfate and herb frost in a mass ratio of 102:48:26:1.
[0053] A Chinese medicine compound preparation, specifically a water pill, is prepared as follows:
[0054] (1) Mix green vitriol, alum and sodium sulfate in appropriate proportions, grind into powder, mix evenly with white vinegar, and the mass ratio of powder to white vinegar is 12:1;
[0055] (2) Dry in a well-lit and ventilated room for 3 months;
[0056] (3) After drying to a moisture content of less than 8%, add the compound proportion of Baicao Frost and grind into a uniform powder;
[0057] (4) Add 0.8 times water to the drug powder obtained in step (3), stir evenly, make pills, and dry at 50°C to obtain water pills of the Chinese medicine compound. The pill weight is 2g.
[0058] Example 3 Chinese medicine compound preparation
[0059] The Chinese herbal compound is composed of green vitriol, alum, sodium sulfate and herb frost in the ratio of 97:52:27:1 by mass.
[0060] A Chinese medicine compound preparation, specifically a capsule, is prepared by: obtaining drug powder by steps (1) to (3) in the preparation method of Example 1, and then filling the powder into a capsule.
[0061] Example 4 Chinese medicine compound preparation
[0062] The Chinese herbal compound is composed of green vitriol, alum, sodium sulfate and herb frost in the ratio of 104:47:23:2 by mass.
[0063] A Chinese medicine compound preparation, specifically a tablet, is prepared by obtaining a drug powder in the same manner as steps (1) to (3) in the preparation method of Example 1, then adding a drug-acceptable carrier, mixing, granulating, drying, and tableting.
[0064] Example 5 Animal experiment on the treatment of chronic nephritis with Chinese medicinal compound preparation
[0065] 1. Experimental Methods
[0066] 1. Experimental Materials
[0067] (1) Animals
[0068] SPF grade SD rats, male, are raised and managed by personnel who have obtained the qualification of laboratory animal management. Breeding unit: Guangdong Medical Laboratory Animal Center, Laboratory Animal Production License No.: SCXK (Yue) 2018-0002, Animal Quality Certificate: 44007200091883.
[0069] Rearing conditions: Sun Yat-sen University (Experimental Animal Center North Campus), Laboratory Animal Use License No.: SYXK (Guangdong) 2017-0081. Temperature 20-25°C; humidity 40%-70%.
[0070] Ventilation rate: greater than 10 times / hour.
[0071] Stocking density: 3 per cage.
[0072] Lighting time: 12 hours (lights on at 7:00 a.m. to off at 7:00 p.m.).
[0073] Feed: SPF grade rat feed
[0074] Drinking water: 121℃(1.0kg / cm 2 ), 30 minutes sterilization high-quality water, in line with the "Drinking Water Quality Standard" (CJ94-2005).
[0075] (2) Drugs
[0076] Test drug: the Chinese medicine compound preparation prepared in Example 1;
[0077] Positive drug: Prednisone acetate tablets, purchased from Zhejiang Xianjun Pharmaceutical Co., Ltd., batch number 210128.
[0078] (3) Reagents:
[0079] Ethyl carbamate, Sinopharm Group;
[0080] BSA, Biyuntian Company;
[0081] Carbon tetrachloride, analytical grade, Luoyang Chemical Reagent Factory;
[0082] LPS, Sigma;
[0083] HE dye, Servicebio;
[0084] Goat anti-rat IgA alpha chain (FITC) (ab97184), abcam;
[0085] DAPI staining solution, Boster Company.
[0086] 2. Dosage and route of administration
[0087] The dose and route of administration of the tested drug were as follows: high dose 2.8 g / kg / d, medium dose 1.4 g / kg / d, and low dose 0.7 g / kg / d. The administration volume of each dose was 10 mL / kg, and the drug was administered orally once a day.
[0088] Dosage and administration route of prednisone acetate tablets: 6 mg / kg / d, administration volume is 10 mL / kg, oral administration once a day.
[0089] 3. Animal grouping and modeling
[0090] (1) Grouping
[0091] 60 SPF SD rats, male, weighing 180-220 g, were randomly divided into the following 6 groups according to their body weight, with 10 rats in each group:
[0092] A. Normal group,
[0093] B. Model group,
[0094] C. Low-dose Chinese medicine group (0.7 g / kg / d),
[0095] D. Chinese medicine medium dose group (1.4g / kg / d),
[0096] E. High-dose Chinese medicine group (2.8 g / kg / d),
[0097] F. Prednisone acetate group (6 mg / kg / d).
[0098] (2) Make a mock
[0099] Except for the normal group, the rats in the other groups were induced to establish models:
[0100] 1 to 6 weeks, intragastrically administer 400 mg / kg BSA every other day;
[0101] 1 to 9 weeks, castor oil 0.5 mL + CCl injected subcutaneously once a week 4 0.1mL;
[0102] At 6 and 8 weeks, 0.05 mg of LPS was injected into the tail vein once.
[0103] 4. Medication treatment
[0104] From 4 to 10 weeks, rats in each group were gavaged with the drug according to the dose, once a day;
[0105] The normal group and model group were given distilled water as control.
[0106] 5. Experimental inspection
[0107] (1) General condition and weight observation
[0108] The rats' diet, stool, hair, breathing, mental state and other general conditions and behavioral performance were observed every day. The rats were weighed once a week.
[0109] (2) Urine test
[0110] After the last administration, the rats were placed in a metabolic cage, their urine was collected, and the 24-hour urine volume was recorded. The urine was stored at -80°C, and after thawing, the urine urea nitrogen (BUN), urine creatinine (CRE), and urine total protein (TP) were measured using an automatic urine biochemical analyzer. The 24-hour urine total protein content (g) was calculated as total urine protein content (g / L) × 24-hour urine volume (L). The urine red blood cell count was examined by urine sediment microscopy.
[0111] (3) Plasma and kidney tissue collection
[0112] After collecting urine, the rats in each group were anesthetized and the abdominal cavity was opened; about 1.5 mL of blood was collected from the inferior vena cava and anticoagulated with EDTA; the blood was centrifuged at 10000 RPM for 1 min to separate the plasma and store it at -80°C. After blood was collected from the rats in each group, the left kidney was taken and fixed with 4% paraformaldehyde for more than 24 hours for pathological examination and immunofluorescence staining.
[0113] (4) Blood biochemical test
[0114] The blood urea nitrogen (BUN), creatinine (CRE), albumin (ALB), total protein (TP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in plasma were detected using an automatic biochemical analyzer.
[0115] (5) Renal histopathological examination
[0116] The renal tissue was fixed with 4% paraformaldehyde for more than 48 hours, and 5um paraffin sections were made and stained with HE; the sections were observed under an optical microscope (400×) and pathological scores were performed. Renal pathology scoring standard (Paller method): tubules were obviously dilated, and epithelial cell degeneration or necrosis was considered abnormal tubules. No dilation of tubules and normal epithelial cell structure were scored as 0 points; abnormal tubules accounted for about 1 / 4 of all tubules in the field of view, scored 1 point; abnormal tubules accounted for about 2 / 4 of all tubules in the field of view, scored 2 points; abnormal tubules accounted for about 3 / 4 of all tubules in the field of view, scored 3 points; almost all tubules in the field of view were abnormal tubules, scored 4 points.
[0117] (6) IgA immunofluorescence test
[0118] Kidney tissues were fixed with 4% paraformaldehyde for more than 48 hours, and 5 μm paraffin sections were made; microwave antigen repair, BSA blocked nonspecific antigens, FITC-labeled IgA fluorescent antibody was added, and the cells were kept in the dark at 4°C overnight; PBS was washed 3 times, 5 minutes each time, PBS was removed, and DAPI dye solution was added to incubate at room temperature in the dark for 10 minutes to stain the nucleus. PBS was washed 3 times, 5 minutes each time, PBS was removed, and anti-fluorescence quencher was added to seal the slices. Fluorescent images of the slices were taken with an inverted fluorescence microscope at an appropriate magnification, and the fluorescence intensity was analyzed using ImageJ image processing software.
[0119] (7) Data processing
[0120] The experimental data were statistically processed using GraphPad Prism9 biostatistics software: the quantitative data were expressed as Mean±SD and analyzed using analysis of variance combined with Dunnett's multiple comparison method; the categorical data were analyzed using the Kruskal-Wallis rank sum test combined with Dunnett's multiple comparison method.
[0121] 2. Experimental Results
[0122] 1. General status and weight observation results
[0123] The fur of the rats in the normal group was dense, neat and shiny, and there were no obvious abnormalities in growth, eating and spontaneous activities. From week 1 to 10 of the experiment, compared with the normal group, the fur of the rats in the model group and each drug group was duller, the activity was reduced, the spirit was poor, and the weight decreased, but there was no statistical difference (P>0.05). Some animals died, and there was no significant difference among the modeling groups. The specific number of deaths in each group is as follows: B. 1 in the model group, D. 1 in the Chinese medicine medium dose group, E. 2 in the Chinese medicine high dose group, and F. 2 in the prednisone acetate group. The weight data are shown in Tables 1 and 2.
[0124] Table 1 Body weight observation results from 0 to 5 weeks (g, Mean±SD, n=10).
[0125]
[0126] Note: There was no significant difference between each group and the model group (P>0.05).
[0127] Table 2 Body weight observation results from 6 to 10 weeks (g, Mean±SD, n=8-10).
[0128]
[0129] Note: There was no significant difference between each group and the model group (P>0.05).
[0130] 2. Blood biochemical test results
[0131] Compared with the normal group, the blood CRE, blood BUN, blood ALT and blood AST in the model group increased significantly / P<0.05 or <0.01), and there was no significant difference in blood TP and blood ALB (P>0.05). Compared with the model group, the blood CRE and blood BUN in the high-dose group of the Chinese herbal compound preparation and the prednisone acetate group were significantly reduced (P<0.05 or 0.01); the blood ALT in the high-dose group of the Chinese herbal compound preparation and the prednisone acetate group was significantly reduced (P<0.05); the blood AST in the medium- and high-dose groups of the Chinese herbal compound preparation and the prednisone acetate group (P<0.05); there was no significant difference in blood TP and blood ALB between the various dose groups of the Chinese herbal compound preparation and the prednisone acetate group (P>0.05). Detailed results are shown in Figure 1 shown.
[0132] 3. Urine biochemical test results
[0133] Compared with the normal group, the 24-hour urine volume, urine TP, 24-hour urine TP, urine CRE, and urine BUN content in the model group were significantly increased (P<0.05 or 0.001). Compared with the model group, there was no significant difference in 24-hour urine volume in each drug group (P>0.05); there was no significant difference in urine TP in each dose group of the Chinese herbal compound preparation (P>0.05), and urine TP in the prednisone acetate group was significantly reduced (P<0.001); there was no significant difference in 24-hour urine TP in each dose group of the Chinese herbal compound preparation (P>0.05), and 24-hour urine TP in the prednisone acetate group was significantly reduced (P<0.05); urine CRE in each dose group of the Chinese herbal compound preparation had a decreasing trend, but there was no statistical difference (P>0.05), and urine CRE in the prednisone acetate group was significantly reduced (P<0.05); urine BUN in the high-dose Chinese herbal compound preparation group and the prednisone acetate group was significantly reduced (P<0.05). Detailed results such as Figure 2 shown.
[0134] 4. Urine red blood cell count results
[0135] like Figure 3 As shown, compared with the normal group, the urine red blood cell count in the model group was significantly increased (P<0.001); compared with the model group, there was no significant difference in the urine red blood cell count in each dose group of the Chinese herbal compound preparation (P>0.05), and the urine red blood cell count in the prednisone acetate group was significantly reduced (P<0.05).
[0136] 5. Renal histopathological examination results
[0137] Macroscopic observation showed that the kidneys of rats in the normal control group were smooth without swelling, reddish brown, soft and shiny; the kidneys of rats in the model group and each drug-treated group were dark brown and hard.
[0138] HE staining and observation under a 400× microscope showed that the normal control group had normal kidney structure, no swelling or degeneration of the renal tubules, and normal glomeruli; the model group had obvious changes in kidney structure, dilation of the renal tubules, and visible protein casts; compared with the model group, the above pathological changes in the various dose groups of the Chinese medicine compound preparation and the prednisone acetate group were improved. Representative figures are shown in Figure 2. Figure 4 shown.
[0139] Compared with the normal group, the renal pathology score in the model group increased significantly (P<0.001). Compared with the model group, the scores of the Chinese medicine compound preparation groups and the prednisone acetate group showed a decreasing trend, but there was no statistical difference (P>0.05). Figure 5 shown.
[0140] 6. IgA immunofluorescence test results
[0141] like Figure 6As shown, the renal tissue of the model group had a stronger IgA immunofluorescence reaction, while the normal group had no IgA fluorescence reaction; compared with the model group, the IgA immunofluorescence of each drug group tended to decrease.
[0142] like Figure 7 As shown, compared with the model group, the IgA immunofluorescence in the high-dose Chinese medicine compound preparation group and the prednisone acetate group was significantly reduced (P<0.05).
[0143] In summary, compared with the normal group, the 24-h urine volume, urine TP, 24-h urine TP, urine CRE, urine BUN, urine red blood cell count, blood CRE, blood BUN, blood ALT and blood AST in the model group were significantly increased (P<0.05 or 0.001), the renal pathological changes were obvious, and the IgA immunofluorescence positive reaction was obvious, indicating that the renal disease model was successfully established.
[0144] Compared with the model group, blood CRE, blood BUN and blood ALT in the high-dose group of the Chinese herbal compound preparation were significantly reduced (P<0.05); blood AST in the medium and high-dose groups of the Chinese herbal compound preparation was significantly reduced (P<0.05); renal pathological changes in each dose group of the Chinese herbal compound preparation were improved; IgA immunofluorescence in the high-dose group of the Chinese herbal compound preparation was significantly reduced (P<0.05).
[0145] Creatinine CRE and urea nitrogen BUN are the end products of nitrogen-containing organic matter and protein metabolism, respectively, which are filtered out from the glomerulus. When the glomerular filtration function is impaired, blood creatinine and urea nitrogen increase due to retention. Urine total protein TP refers to the protein content in urine. The higher the content, the worse the kidney filtration function. Serum alanine aminotransferase ALT and serum aspartate aminotransferase AST are important indicators for judging liver damage. IgA deposition in the kidney is one of the characteristics of nephritis.
[0146] Therefore, the Chinese medicinal compound preparation of the present invention has an obvious preventive and therapeutic effect on renal damage in rats with chronic nephritis and nephropathy model, which is mainly manifested in significantly reducing blood CRE, blood BUN and renal IgA deposition.
[0147] Example 6 Clinical therapeutic effect of Chinese medicine compound preparation
[0148] Drug: the Chinese medicine compound preparation of Example 1;
[0149] Usage: Oral;
[0150] Dosage: 3 times a day, 3-9 capsules each time.
[0151] Treatment location: Qingfeng Village Health Center, Nanjiang Town, Pingjiang County, Yueyang City, Hunan Province
[0152] Doctor: Wang Yulong, Dr. Wang Yulong is the 13th generation descendant of a family-established nephrology specialist and an assistant general practitioner. He has more than 30 years of rich experience in the use of traditional Chinese medicine to treat kidney disease.
[0153] The treatment cases are listed in Table 1:
[0154] Table 1
[0155]
[0156]
[0157]
[0158] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A Chinese medicine compound, It is characterized in that According to the mass ratio, it is composed of green vitriol, alum, sodium sulfate and herb frost in the ratio of (97-104): (47-52): (23-27): (1-2); among them, green vitriol, alum and sodium sulfate are all processed with vinegar.
2. The Chinese medicinal compound according to claim 1, It is characterized in that According to the mass ratio, it is composed of green vitriol, alum, sodium sulfate and herb frost in the ratio of (100-102): (48-50): (25-26): (1-2).
3. Use of the Chinese medicinal compound according to claim 1 or 2 in the preparation of medicines for treating chronic nephritis.
4. Use of the Chinese medicinal compound according to claim 1 or 2 in the preparation of a medicament for treating IgA chronic nephritis.
5. Use of the Chinese medicinal compound according to claim 1 or 2 in the preparation of a medicine for treating nephrotic syndrome.
6. A pharmaceutical preparation for treating chronic nephritis or nephrotic syndrome, It is characterized in that Contains the Chinese medicinal compound according to claim 1 or 2.
7. The pharmaceutical preparation according to claim 6, It is characterized in that The Chinese medicine compound according to claim 1 or 2 is prepared according to the following method and then made into a pharmaceutical dosage form: (1) Mix green vitriol, alum and sodium sulfate, grind them into powder, mix them evenly with white vinegar, and the mass ratio of powder to white vinegar is (8-12):1; (2) Then place it outdoors for 2-3 months without rain; (3) After drying to a moisture content of less than 8%, add Baicao Frost and grind into a uniform powder.
8. A water pill, It is characterized in that The Chinese medicinal compound according to claim 1 or 2 is ground into powder, processed and made into water pills.
